Cisplatin news

All news on Cisplatin (also known as Cis-diamminedichloroplatinum(II) and Platinol): plants, production capacities, investments and involved companies.

27 February 2026

Merck's KEYTRUDA and Padcev Cut Event-Free Survival Risk by 47% and Mortality by 35% in Cisplatin-Eligible Bladder Cancer Patients

KEYTRUDA plus Padcev improves survival and reduces recurrence in muscle-invasive bladder cancer, showing potential as a new standard for cisplatin-eligible patients.
18 February 2026

Johnson & Johnson's RYBREVANT FASPRO™ Gains FDA Breakthrough Status for Advanced Head and Neck Cancer

FDA grants Breakthrough Therapy Designation to RYBREVANT FASPRO™ for HPV-unrelated head and neck cancer after platinum-based chemotherapy and PD-1/PD-L1 inhibitor.
7 January 2026

Merck Launches Phase 3 Trial of Calderasib with KEYTRUDA QLEX for Advanced NSCLC

Merck's KANDLELIT-007 trial tests calderasib and KEYTRUDA QLEX for KRAS G12C-mutant NSCLC, focusing on progression-free survival and overall response.
17 December 2025

Merck's KEYTRUDA and Padcev Enhance Survival in Cisplatin-Eligible MIBC Patients

KEYTRUDA and Padcev improve survival and response rates in MIBC patients, showing promise as perioperative treatment with consistent safety profiles.
21 November 2025

Merck's KEYTRUDA and Padcev Approved by FDA for Bladder Cancer Treatment

FDA approves first PD-1 inhibitor plus ADC regimens for cisplatin-ineligible muscle-invasive bladder cancer, based on KEYNOTE-905 trial results showing significant EFS improvement.
29 October 2025

Merck's KEYTRUDA Approved in EU for Treating Resectable LA-HNSCC

KEYTRUDA gains EU approval as the first anti-PD-1 therapy for resectable LA-HNSCC with PD-L1 expression, based on KEYNOTE-689 results.

Who will be producing Cisplatin in the future?

Find out with chemXplore Alpha

Learn more